Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01579695 · ClinicalTrials.gov registry record
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
A clinical trial, sponsored by Theratechnologies.
- Terminated
- Registry status
- 391
- Enrollment target
NCT01579695: Clinical Trial study, sponsored by Theratechnologies.
NCT01579695 is a clinical trial that was terminated before completion, run by Theratechnologies. The registered enrollment target is 391 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01579695 was terminated before completion, sponsored by Theratechnologies.
- TERMINATED
- Registry status
- 391 participants
- Enrollment target
Study Summary
The purpose of this observational, 10-year, prospective cohort study is to assess the potential safety concerns of long-term exposure to EGRIFTA® in HIV-infected subjects with abdominal lipohypertrophy compared with a similar group of subjects not exposed to EGRIFTA®.
Interventions
- DRUG Tesamorelin for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 391 participants |
| Start Date | 2013-02 |
| Est. Completion | 2018-08 |
Why NCT01579695 stopped before completion
NCT01579695 is an observational study that tracks outcomes without assigning an intervention. The registered 391 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Tesamorelin for injection is the first listed.
NCT01579695 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01579695 about?
NCT01579695 is a clinical study titled "Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®". The purpose of this observational, 10-year, prospective cohort study is to assess the potential safety concerns of long-term exposure to EGRIFTA® in HIV-infected subjects with abdominal lipohypertrophy compared with a similar group of subjects not exposed to EGRIFTA®.
What is the current status of trial NCT01579695?
This trial is currently terminated. The enrollment target is 391 participants. The study started on 2013-02. Estimated completion is 2018-08.
What interventions are being tested in trial NCT01579695?
The interventions under investigation include: Tesamorelin for injection (DRUG).
Who is sponsoring clinical trial NCT01579695?
This trial is sponsored by Theratechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
- NCT06625775 · 392 participants · Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT07220967 · 392 participants · Phase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- NCT07290036 · 392 participants · Phase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia